VIDEO: Ocaliva shows long-term effects on immune, inflammatory markers

VIENNA — In this exclusive video from the International Liver Congress 2019, Gideon M. Hirschfield, MD, from the Toronto Center for Liver Disease and the University of Toronto in Canada, discusses the long-term effects of Ocaliva in patients with primary biliary cholangitis on immune and inflammatory markers.
In the study Hirschfield presented this year, Ocaliva (obeticholic acid, Intercept) demonstrated not only improvements in markers of cholestasis but also improved markers of inflammation including C-reaction protein.
“Studies like this are very important as we develop new drugs

Source link

Related posts

miR-146a Deficiency Accelerates Hepatic Inflammation Without Influencing Diet-induced Obesity in Mice


Eosinophilic Esophagitis Responds to Steroid


Hepatitis D coinfection found in ‘household clusters’ in Cameroon


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy